Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1-year follow-up using gross motor function measure.

Department of Neuropaediatrics and Muscle Disorders, Children's University Hospital, Freiburg, Germany.
European Journal of Neurology (Impact Factor: 3.85). 11/2001; 8 Suppl 5:120-6. DOI: 10.1046/j.1468-1331.2001.00044.x
Source: PubMed

ABSTRACT One of the main goals when treating spasticity is to relieve pain and improve function. Intramuscular injection of botulinum toxin type A (BTX-A) has gained widespread acceptance in the treatment of spastic cerebral palsy. Several studies have clearly shown the short-term functional benefit of BTX-A treatment. Information is limited, however, on the efficacy of medium and long-term regimens, using repeated injection of BTX-A. The aim of the present open-label, prospective study was to evaluate functional outcome in children with spastic cerebral palsy after 1 year of treatment with BTX-A, using the Gross Motor Function Measure (GMFM) as a validated outcome measure. Patients (n=25, age 1.5--15.5 years) were treated with BTX-A for adductor spasm (n=12) or pes equinus (n=13). The local effect was evaluated using passive range of motion and modified Ashworth Scale. Apart from a significant improvement in joint mobility and reduction of spasticity compared to pretreatment values (P < 0.01), we demonstrated a significant improvement of gross motor function after 12 months of treatment, with a median gain of 6% in total and goal scores (P < 0.001). An increase in GMFM scores was particularly evident in younger and moderately impaired children (Gross Motor Function Classification System level III). Whether the observed improvement in gross motor function in children with cerebral palsy is specifically related to therapy with BTX-A or represents at least in part the natural course of motor development still needs clarification.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: With evidence for an atrophic effect of botulinum toxin type A (BoNT-A) documented in typically developing muscles, this study investigated the immediate morphological alterations of muscles in children with cerebral palsy (CP) after BoNT-A treatment. Fifteen children (10 males, five females; age range 5-11y, mean age 8y 5mo, SD 1y 10mo) with spastic diplegic CP [Gross Motor Function Classification System Levels I (n=9) and II (n=6)] receiving BoNT-A injections for spasticity management were included. None of the children was a first-time receiver of BoNT-A. Magnetic resonance imaging and Mimics software assessed muscle volume, timed 2 weeks before and 5 weeks after injection. All participants received BoNT-A bilaterally to the gastrocnemius muscle, and five participants also received BoNT-A bilaterally to the medial hamstring muscles. Functional assessment measures used were the 6-Minute Walk Test (6-MWT), the Timed Up and Go (TUG) test, and hand-held dynamometry. Whilst total muscle group volume of the injected muscle group remained unchanged, a 4.47% decrease in the injected gastrocnemius muscle volume (p=0.01) and a 3.96% increase in soleus muscle volume (p=0.02) was evident following BoNT-A. There were no statistically significant changes in function after BoNT-A as assessed by the TUG. There was also no statistically significant change in distance covered in the 6-MWT. Muscle strength, as assessed using hand-held dynamometry was also not statistically different after BoNT-A treatment. Muscle volume decreases were observed in the injected muscle (gastrocnemius), with synergistic muscle hypertrophy that appeared to compensate for this decrement. The 4% to 5% decrease in the volume of BoNT-A injected muscles are not dramatic in comparison to reports in recent animal studies, and are a positive indication for BoNT-A, particularly as it also did not negatively alter function.
    Developmental Medicine & Child Neurology 06/2013; · 2.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In direct-gap semiconductors, low temperature states of high-density electrons and holes show collective quantum mechanical effects such as the formation of electron-hole liquid and exciton condensation. In the usual band-to-band excitation, the temperature of the carriers remains high within their lifetime. However, if we create electron-hole pairs through the Mott transition of excitons, we can reduce the initial temperature. In this report, we show the results of femtosecond time-resolved emission spectra of electron-hole pairs created by the exciton resonance excitation in CuCl
  • [Show abstract] [Hide abstract]
    ABSTRACT: Many studies have demonstrated the effectiveness of botulinum toxin injections in order to decrease spasticity in cerebral palsy. However it is essential to carefully assess children to be treated, and the muscles which need to be injected. Injections of soleus in dynamic equinus without fixed contrature in very young children provide the best results, but other muscles may be injected such as upper limbs muscles. Injections have mainly a functional purpose, but sometimes they may contribute to prevent fixed contractures or pain during nursing.
    Archives de Pédiatrie 09/2002; 9(9):928-933. · 0.41 Impact Factor


Available from
May 20, 2014